Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes

Dow Jones

2024-11-02

By Sabela Ojea

Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.

Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month.

Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said.

The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said.

Myriad Genetics wasn't immediately available for comment.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

November 01, 2024 12:34 ET (16:34 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2480776831"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480776831\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2480776831?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-02 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480776831","market":"hk","top_or_hot":-1,"title":"Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. \n</p>\n<p>\n  Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said. \n</p>\n<p>\n  The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said. \n</p>\n<p>\n  Myriad Genetics wasn't immediately available for comment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 12:34 ET (16:34 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-11-02 00:34</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. \n</p>\n<p>\n  Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said. \n</p>\n<p>\n  The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said. \n</p>\n<p>\n  Myriad Genetics wasn't immediately available for comment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 12:34 ET (16:34 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2480776831","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480776831","pubTimestamp":1730478840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month.Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said.The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MYGN":"万基遗传"},"translate_title":"UnitedHealthcare承保范围变化导致Myriad Genetics股价下跌21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n\n\n  Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. \n\n\n  Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said. \n\n\n  The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said. \n\n\n  Myriad Genetics wasn't immediately available for comment. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 01, 2024 12:34 ET (16:34 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}